Document:

Exhibit 10.1

 

JOINT VENTURE AGREEMENT

 

THIS JOINT VENTURE
AGREEMENT (this “Agreement”), is entered into this 07 day of February, 2019, by and between Cannabics
Pharmaceuticals, Inc., a Nevada corporation with an address at #3 Bethesda Metro Center, Suite 700 Bethesda, MD 20814 (“Cannabics”),
and Wize Pharma, Inc., a Delaware corporation with an address at 24 Hanagar Street, PO Box 6653, Hod Hasharon, Israel (“Wize”),
(Cannabics and Wize, each a “Founder”, and collectively, the “Founders”).

 

WHEREAS, the
Founders are interested in incorporating a joint venture company under the laws of Israel for the purpose of researching, developing,
and administering cannabinoid formulations to treat ophthalmic conditions (the “Business”); and

 

WHEREAS, the
Founders desire to set forth in writing certain agreements as hereinafter described regarding the establishment of the joint venture
company and the rights and obligations of the Founders;

 

NOW, THEREFORE,
in consideration of the mutual promises hereinafter contained, the Parties hereto agree as follows:

 

1. Establishment
of the Company

 

1.1 Incorporation
of the Company. The Founders will establish a private company incorporated in Israel, with the name of “WPCP Pharma”
or any other similar name lawfully available (the “Company”). The Founders will file the required documents
to establish the Company within 14 days (as may be extended by mutual written consent) following the Effective Date (as defined
below). Cannabics (the “Incorporator”) shall be responsible for incorporating the Company. The shares of the
Company shall have such rights and restrictions as set forth in the Charter Documents (as defined below), as may be amended from
time to time.

 

1.2       Incorporation
Documents. The shares of the Company shall have such rights and restrictions as set forth in the Charter Documents, as may
be amended from time to time.

 

1.3 Ratification
of Actions Taken Prior to Incorporation. The Company shall ratify the activities of the Incorporator as the incorporator of
the Company.

 

     

     

    

 

1.4 Founder
Representations/Undertakings. Each Founder represents that neither the execution nor the performance of this Agreement violates
any agreement to which he is bound or any provisions of applicable law. Each Founder further agrees to notify the Company immediately
if any conflict with its performance of this Agreement arises. Each Founder agrees to execute any further documents or instruments
reasonably necessary to carry out the purposes or intent of this Agreement. Notwithstanding anything to the contrary in this Agreement,
the Founders agree and acknowledge the following:

 

1.4.1 All
of the activities of the Business shall be carried out according to each Founder’s respective territorial, regulatory and
commercial restrictions, as existing on the date hereof.

 

1.4.2 Without
derogating from the generality of the foregoing, and for the sake of clarity, nothing herein will require Wize to take any action
that is inconsistent or in conflict with its obligations under the Exclusive Distribution and Licensing Agreement with Resdevco
Ltd., dated as of May 1, 2015, as amended and supplemented thereafter.

 

2. Shareholdings

 

2.1Initial
Shareholdings.The issued share capital of the Company upon its incorporation shall be as follows:

 

	Shareholder	 	Ordinary Shares	 	 	Shareholding Percentage	 
	Cannabics	 	 	50,000	 	 	 	50	%
	Wize	 	 	50,000	 	 	 	50	%
	Total:	 	 	100,000	 	 	 	100	%

  

3. Obligations
of the Founders

 

3.1 Notwithstanding
anything to the contrary hereunder, each Founder has, and shall retain, the sole and exclusive ownership of all right, title, and
interest in and to its intellectual property, including any and all developments, modifications, enhancements, improvements, and
derivative works made thereto, and including all patents, copyrights, and other intellectual property rights associated therewith.

 

3.2 Each
Founder acknowledges and agrees that, subject to Section 3.3 below, title to, and all rights and interest in, all materials, products
and deliverables prepared by such Founder in the performance of services for the Company (whether prior to or subsequent to its
incorporation), including, but not limited to, reports, designs, programs, specifications, documentation, manuals, visual aids,
software programs, and any other materials developed and/or prepared by such Founder for the Company (collectively, “Work
Product”), in each case, if and to the extent such services are to be performed by such Founder shall vest in the Company
and shall be deemed to be work made for hire, unless otherwise mutually agreed in writing (such as where the parties agree that
performance of services will result in a limited non-exclusive license for use solely in the Business).  To that end,
(i) to the extent that any such Work Product may not be considered work made for hire, each Founder hereby irrevocably assigns
all right, title and interest therein to the Company without further consideration, and (ii) all such materials shall belong exclusively
to the Company, with the Company having the right to obtain and to hold in its own name, copyrights, trademarks, patents, registrations
or such other protection as may be appropriate to the subject matter, and any extensions and renewals thereof.

 

    2

     

    

 

4. Business
and Management of the Company

 

4.1 Business
of the Company. The Company will engage in all business activities permitted under relevant law; provided, however, that the
Company will focus on the Business.

 

4.2 Business
Plan. Promptly following the Effective Date, the Founders will work together to prepare a mutually acceptable business plan,
which will be completed no later than 30 days after the Effective Date and shall include its initial budget as well as the respective
contribution, if any, of each Founder’s cash, non-cash assets and/or services to the Company (the “Business Plan”),
as such plan may be revised by the Company’s Board of Directors (the “Board”) from time to time. Prior
to the execution of the Business Plan, the Founders will conduct a freedom to operate analysis. The Company will conduct its business
in accordance with the Business Plan.

 

4.3 Budget.
At the beginning of each calendar year after incorporation of the Company, the Company shall prepare a budget for the upcoming
calendar year of operations, the approval of which will be subject to the consent of the Company’s Board of Directors

 

4.4 “Board
of Directors”. The Company’s initial Board shall be comprised of three (3) directors. The Founders, for as long
as such Founder owns at least ten percent (10%) of the issued and outstanding shares of the Company, will each be entitled to recommend
and appoint one director, and the third director shall be an industry expert recommended by Wize and approved by Cannabics. Each
Founder shall be entitled to remove the director appointed by such Founder and appoint a new director instead, at any time, upon
prior written notice to the Company.

 

4.5 Officers.
The initial officers of the Company shall be Noam Danenberg, and Eyal Barad, who shall serve as Co-Chief Executive Officers.

 

4.6 Signatory
Authority. The Board will decide on an appropriate signatory authority for the Company in light of the operational needs of
the Company.

 

4.7Expenses.Until
the Company has a revenue stream or as may otherwise be determined in the Business Plan, each Founder shall be responsible for
fifty percent (50%) of the expenses of the Company, including the incorporation costs and associated legal fees.

 

4.8Information
Rights. The Charter Documents shall provide for information rights to the Founders, such that, except as necessary to comply
with applicable law or contract and subject to any applicable privileges (including the attorney-client privilege), each Founder,
for as long as it holds at least five percent (5%) of the outstanding shares of the Company, will be given reasonable access to
the Company’s employees, agents, properties, books and records for all proper purposes, during normal business hours and
upon reasonable prior notice, the costs of review of which, if any, shall be borne by each Founder seeking to review the same.
The Company will prepare and deliver such financial or other information concerning its business as a Founder may reasonably request,
provided that if the Founder making such request holds less than 5% of the outstanding shares of the Company, the expenses associated
therewith will be borne by such Founder (other than with respect to annual and quarterly financial statements of the Company).

 

    3

     

    

 

4.9Veto Rights.The
Charter Documents shall provide as for veto rights to the Founders, such that, for as long as a Founder holds at least ten percent
(10%) of the outstanding shares of the Company, the Company shall not undertake any of the following actions without first obtaining
the prior written consent of the directors appointed by such Founder: (a) a merger, consolidation, or sale of all or substantially
all of the Company’s assets or shares (other than as part of a drag-along transaction pursuant to Section 7); (b) a liquidation,
dissolution, or winding up of the Company or the termination of the Company’s activities; (c) a fundamental change in the
nature of the Company’s business; (d) any amendment to the Articles of Association of the Company that adversely effects
the rights of such Founder (it being understood that amendments associated with the issuance of shares as part of a financing shall
not be deemed an adverse change); (e) the issuance of any shares, options to acquire shares, or debt securities of the Company;
(f) an increase in the number of directors of the Company to more than three (except in connection with a financing (g) any appointment
or removal of an executive officer of the Company; (h) a transfer, assignment or exclusive license of any intellectual property
that is fundamental to the operation of the Business to any third party (other than as part of a drag-along transaction pursuant
to Section 7); and (i) any “related party transaction” (as shall be defined in the Charter Documents or pursuant to
applicable law).

 

4.10 Necessary
Actions. The Founders will act in such a manner as may be necessary to give effect to the provisions of this Agreement, including
appointing or removing directors, as provided above, causing such directors to give effect to such provisions, and causing its
shares to be voted at a general meeting of shareholders to give effect to such provisions.

 

5. Restrictions
on Share Transfers.

 

5.1 Permitted
Transfers. Each Founder may, at any time, transfer all or part of its shares in the Company (“Shares”) to
an Affiliate (as defined below), provided that at the time of such transfer such transferee will execute such instruments as may,
in the Company’s reasonable opinion, be necessary to ensure that (a) such transferee has acceded to be bound by all of the
terms of this Agreement, and (b) the Founder remains responsible for such transferee’s performance of its obligations hereunder;
and further provided that such transfer shall remain valid for only so long as such Affiliate remains an Affiliate of the Founder.
Thereafter any reference in this Agreement to a Founder’s shareholdings shall include all Shares held by such Founder and
its authorized transferees pursuant to this Section 5.1. Any change in the relationship of the Affiliate holding an interest in
Company and such Founder, such that the Affiliate ceases to be an Affiliate, shall obligate such Founder promptly to re-acquire
the Shares from such Affiliate. “Affiliate” means, with respect to any person, any other person directly and/or
indirectly controlling, directly and/or indirectly controlled by, or under direct and/or indirect common control with, such person.

 

    4

     

    

 

5.2 Right
of First Refusal

 

Until the closing of
a Company Sale or an IPO (as such terms are defined below), each Founder for so long as it holds at least ten percent (10%) of
the issued and outstanding shares of the Company (a “Qualified Founder”) shall be entitled to a right of first
refusal on all transfers of Shares by the other Founder. No Founder shall sell, assign, charge (other than creation of a lien pursuant
to Section 5.2.5 below) or transfer (together, “Transfer”) all or any of the Shares owned by such Founder except
as set forth below (and except for the permitted transfer of Shares to an Affiliate under Section 5.1 above):

 

5.2.1In the
event a Founder (the “Offeror”) proposes to Transfer any of his Shares (the “Offered Shares”)
to any person or entity (the “Proposed Transfer”), the Offeror shall promptly request (the “Offeror’s
Request”) that the Company deliver to the other Founder, provided that the other Founder is a Qualified Founder, a written
notice containing the identity of the proposed transferee, the number of Shares included in the Proposed Transfer, and the terms
and conditions concluded in good faith of the Proposed Transfer (the “Offeror’s Notice”), so as to enable
the other Founder to have the opportunity to exercise their right of first refusal pursuant to this Section 5.2. The Company shall
comply with the Offeror’s Request by sending the Offeror’s Notice to the other Founder.

 

5.2.2The Qualified
Founder shall have the right to purchase all (and not less than all) of the Offered Shares pursuant to the terms of the Offeror’s
Notice by sending a written notice (the “Acceptance Notice”) to the Company within thirty (30) days from receipt
of the Offeror’s Notice (the “Notice Period”).

 

5.2.3If the
Acceptance Notice is in respect of less than the number of Offered Shares or is not timely provided, then the Offeror shall be
entitled to Transfer all (but not less than all) of the Offered Shares to the proposed transferee; provided, however, that in no
event shall the Offeror Transfer any of the Offered Shares to any transferee on terms more favorable to the transferee than those
mentioned in the Offeror’s Notice, and provided, further, that such Transfer must be closed within 120 days after the expiration
of the Notice Period or the Proposed Transfer shall again be subject to the provisions of this Section 5.2.

 

5.2.5Should
a Founder create a lien on his Shares, such Founder shall be obligated to inform the beneficiary of the lien of the existence of
the right of first refusal and that any exercise of the lien shall be deemed a Transfer which is subject to the provisions of this
Section 5.2.

 

5.2.6“Company
Sale” means a merger, business combination, sale of shares or any other similar transaction involving the Company, in
which the shareholders of the Company immediately prior to the merger, business combination or other similar transaction will own,
as a result of which and immediately after the consummation (including all stages) thereof, less than the majority of shares of
the surviving entity; in each case, whether as one transaction or a series of related transactions. “IPO” means
an initial public offering of the shares of the Company.

 

    5

     

    

 

6.
Co-Sale/Tag-Along Right.

 

6.1 Until
the closing of a Company Sale or an IPO, subject at all times to the provisions of Section 5.2 (Right of First Refusal) above,
in the event of any Proposed Transfer by a Founder, other than a permitted transfer of Shares pursuant to Section 5.1 above, each
Qualified Founder shall have the right, within fourteen (14) days after receipt of the Offeror’s Notice, to participate pro-rata
in the Proposed Transfer by sending the Acceptance Notice, in which it shall designate how many shares it wishes to sell up to
its pro-rata share. Each participating Qualified Founder’s pro-rata co-sale right shall be expressed by a fraction, the numerator
of which is the number of outstanding shares of the Company then held by the Founder, and the denominator of which is the sum of
(i) the aggregate number of shares of the Company then held by all the shareholders of the Company exercising co-sale rights, plus
(ii) the aggregate number of outstanding shares of the Company then held by the Offeror, multiplied by 100. If a Founder does not
respond to the Offeror’s Notice within the aforesaid time period, it shall be deemed to have waived its right to participate
in such Transfer.

 

6.2 If
the Acceptance Notice is not timely provided, then the Offeror shall be entitled to Transfer all (but not less than all) of the
Offered Shares to the proposed transferee; provided, however, that in no event shall the Offeror Transfer any of the Offered Shares
to any transferee on terms more favorable to the transferee than those mentioned in the Offeror’s Notice, and provided, further,
that such Transfer must be closed within 120 days after the expiration of the Notice Period or the Proposed Transfer shall again
be subject to the provisions of this Section 6.

 

7.
Compulsory Sale - Drag-Along.

 

7.1 In
the event that prior to an IPO, any person or entity (the “Bidder”) makes a bona fide offer to acquire or purchase
(i) all of the issued share capital of the Company or (ii) all or substantially all of the Company’s assets (the “Offered
Transaction”), and shareholders holding at least 75% of the issued share capital of the Company indicate their acceptance
of the Offered Transaction (the “Majority Selling Shareholders”), and the Offered Transaction is approved by
a majority of the Board, then the Company shall deliver notice thereof to all shareholders (the “Drag-Along Notice”)
and each shareholder will (a) vote its shares in the Company in favor of the Offered Transaction and any decision necessary therefor
(including the appointment of a representative of the Majority Selling Shareholders as proxy on its behalf for all matters reasonably
necessary for the Offered Transaction and the implementation thereof) at every meeting called with respect thereof or any matters
pertaining thereto, (ii) exercise their means of control in the Company in order for the Company to execute all necessary
agreements and documents and to take all such actions reasonably required for the approval and implementation of the Offered Transaction,
(iii) execute all necessary agreements and documents and take all such actions as may be reasonably required in connection
therewith, and (iv) sell all its shares and other securities in accordance with the terms of the Offered Transaction; provided,
however that if the Offered Transaction is not consummated within a period of 180 days after the date of the Drag-Along Notice,
the Offered Transaction shall once again be subject to the terms of this Section.

 

    6

     

    

 

7.2 Each
shareholder shall appear in person or by proxy at any annual or special general meeting for the purpose of obtaining a quorum and
shall vote its shares, either in person or by proxy, at any annual or special meeting called for the purpose of voting on the Offered
Transaction or any matter reasonably related thereto (including appointment of a representative appointed by the Majority Selling
Shareholders as proxy on their behalf for all matters reasonably necessary for the transaction and the implementation thereof)
or by written consent of shareholders with respect to the Offered Transaction, in favor of the Offered Transaction and any decision
necessary therefor (including the appointment of a representative appointed by the Majority Selling Shareholders as proxy on their
behalf for all matters reasonably necessary for the transaction and the implementation thereof) in accordance with this Section
7. Without limitation of the foregoing, upon a failure by a shareholder to comply with this Section 7, such shareholder hereby
irrevocably appoints any designee nominated from time to time by the Board to execute on behalf of such shareholder any and all
documents, instruments, deeds and agreements that are required to be executed by the shareholders pursuant to this Section 7.

 

7.3 Notwithstanding
the foregoing, a shareholder will not be required to comply with the provisions of Sections 7.1 and 7.2 unless: (i) the liability
for indemnification, if any, of such shareholder in the Offered Transaction and for the inaccuracy of any representations and warranties
made by the Company or its shareholders in connection therewith is several and not joint with any other person who is not an Affiliate
of such shareholder (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any shareholder of any of identical representations, warranties and
covenants provided by all shareholders), and is pro rata in proportion to, and does not exceed, the amount of consideration payable
to such shareholder in connection with such Offered Transaction; and (ii) upon the consummation of the Offered Transaction, each
shareholder will receive the same form of consideration and the same portion of the aggregate consideration that such shareholder
would have received if such aggregate consideration (whether in the form of cash, securities or otherwise) had been distributed
by the Company in complete liquidation pursuant to the rights and preferences set forth in the Charter Documents as in effect immediately
prior to such transaction.

 

8. Pre-Emptive
Right

 

Until an IPO or Company
Sale, each shareholder holding at least 5% of the outstanding share capital of the Company (a “Qualified Shareholder”)
shall have a pre-emptive right to purchase New Securities (as defined in Section 8.1) that the Company may, from time to time,
propose to sell and issue.

 

8.1 In
this Section 8, “New Securities” shall mean any shares of the Company, whether now or hereafter authorized,
and rights, options, convertible instruments or warrants to purchase said shares, and securities of any type whatsoever that are,
or may become, convertible into said shares, other than (i) employee stock options and employee share grants under the Company’s
equity incentive plans; (ii) issuances of Company securities in connection with a bona fide loan or credit facility of a third
party financial lender; (iii) issuance of Company securities in an IPO of the Company; (iv) issuances of Company securities pursuant
to an acquisition by the Company of another company or business; (v) issuances of Company securities in connection with any pro
rata stock splits, dividends, distributions, combinations, reclassifications or similar events; and (vi) issuances exempted from
preemptive rights if approved by the shareholders owning at least 75% if the outstanding shares of the Company.

 

    7

     

    

 

8.2 Any
New Securities to be issued by the Company shall first be offered by the Board by written notice of offer to the Qualified Shareholders
(the “Rights Notice”) pro rata to their respective holdings then held by them as of the date of the Rights
Notice. Such Rights Notice shall state the terms, including without limitation the price per share, of the proposed allotment,
and any such shareholder may accept such offer, as to all or any part of the shares so offered to him, by giving the Company written
notice of acceptance within twenty (20) days after being served with the Rights Notice and effecting full payment therefore thereafter.
Any of the New Securities which a Qualified Shareholder fails or declines to acquire as aforesaid shall be re-offered, in the manner
prescribed in the foregoing provisions of this Section 8.2, to the other Qualified Shareholders who submitted notices of acceptance
as to all the New Securities initially offered to them pursuant hereto, in proportion to their respective shareholdings. Even if
the Qualified Shareholders who elect to purchase New Securities elect to purchase in the aggregate less than 100% of the New Securities,
the New Securities so elected to be purchased shall be sold to such shareholders in accordance with such elections.

 

8.3 Any
of the New Securities which are not accepted by the Qualified Shareholders as aforesaid may be subsequently allotted without restriction,
but only on terms no more favorable to the allottee than the terms offered to the Qualified Shareholders. Any of the New Securities
not so allotted within ninety (90) days from the expiration of the re-offer described above shall again be subject to all the provisions
of this Section 8.

 

9.
Effective Date

 

This Agreement shall
become effective on the date (the “Effective Date”) that is one business day following receipt of an opinion, within
30 days from the date of signing, from a mutually selected third party describing the regulatory pathway for eye drops containing
cannabinoids or cannabinoid strings (the “Opinion”). If the Opinion is not received within 30 days of the date hereof,
this Agreement shall become null and void unless otherwise extended by mutual agreement of the parties.

 

10. Mutual
Share Issuances

 

10.1 Upon the
Effective Date (i) Wize shall issue to Cannabics 900,000 shares of its common stock (the “Wize Shares”),
which represent a value of $909,933, calculated using a price per share equal to the weighted-average price per share of its
common stock as traded during the sixty-day period ending on February 5, 2019 (the “60-Day VWAP”), and
(ii) Cannabics shall issue to Wize 2,263,944 shares of its common stock (the “Cannabics Shares” and
together with the Wize Shares, the “Restricted Shares”), which represent a value of equals of $909,933,
calculated using a price per share equal to the weighted-average price per share of its common stock as traded during the
sixty-day period ending on February 5, 2019. All of these issued Restricted Shares shall be free of free of any mortgage,
pledge, lien, royalty obligations, conditional sale agreement, security agreement, encumbrance or other charge (collectively,
“Liens”), subject to any restrictions on transfer under applicable securities Laws and this Agreement.
Notwithstanding the above, the Founders are committed to share and provide the necessary cash payments for any of the
Company’s operations as per the Business Plan within 3 days of the Company’s demand for such cash request.

 

    8

     

    

 

10.2
The Restricted Shares Are Not Registered. Each of the Founders hereby acknowledges that the Restricted Shares will not be
issued by the Founders pursuant to a registration statement under the Securities Act, and therefore they may be required to be
held for an indeterminate period. The Restricted Shares are issued in reliance upon a specific exemption from the registration
requirement of the Securities Act which depends, in part, upon the accuracy of the representations, warranties, and agreements
of each Founder set forth in this Section 10.

 

10.3 Representations
of the Founders.

 

10.3.1 Each
Founder is acquiring the applicable Restricted Shares for such Founder’s own account as principal, not as a nominee or agent,
for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in
part, which resale, distribution or fractionalization would violate the Securities Act. Each Founder agrees that a legend to the
foregoing effect may be placed upon any and all certificates issued representing the Restricted Shares. Further, each Founder does
not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such
person or to any third person, with respect to the Restricted Shares.

 

10.3.2 Each
Founder is sophisticated and experienced in investment matters, and, as a result, is in a position to evaluate an investment in
the other Founder. Each Founder is aware that an investment in the other Founder involves a high degree of risk, may result in
a lack liquidity, and places substantial restrictions on transferability of interest. Each Founder has sufficient financial resources
available to support the loss of all or a portion of the value of the Restricted Shares, has no need for liquidity in connection
with the Restricted Shares, and is able to bear the economic risk of such investment.

 

11. [RESERVED]

 

12. Confidentiality

 

12.1 Each
Founder agrees to maintain in confidence and trust, and not disclose or make any unauthorized use of, whether for his own personal
benefit or for the benefit of others, any proprietary or confidential information of the Company, including without limitation,
trade secrets, know-how, business plans, and marketing plans, whether documentary, written, oral or computer generated. The Company’s
confidential information does not include information that is now, or hereafter becomes, through no act or failure to act on the
part of a Founder, generally known to the public or information which is generally known in the trade or industry, which is not
gained as result of a breach of this Agreement.

 

    9

     

    

 

12.2 Press
Release. Neither Founder shall issue any press release or public announcement concerning this Agreement or the Company without
obtaining the prior written consent of the other Founder hereto, which consent shall not be unreasonably withheld, except as may
be required by applicable securities laws, in which case, the publishing Founder shall use reasonable commercial efforts to send
the draft public announcement to the other Founder prior to publication thereof.

 

13. Non-Compete,
Non-Solicitation and Right Of First Refusal.

 

13.1 For
so long as Cannabics either (a) performs services for the Company or (b) holds at least five percent (5%) of the shares of the
Company, Cannabics shall refrain from developing, investing in (other than through its holding of the Wize Shares issued hereunder),
promoting, or selling any ophthalmology product.

 

13.3 For
so long as Wize either (a) performs services for the Company or (b) holds at least five percent (5%) of the shares of the Company,
Wize shall refrain from developing, investing in (other than through its holding of the Cannabics Shares issued hereunder), promoting,
or selling any cannabis-based products.

 

13.4 Subject
to non compete clause section 13.1 and 13.2 above, in case the Company decided for any reason not to invest in a new venture relating
any ophthalmology or cannabis-based products which was proposed to the Company by any of the Founders, the Company will have 10%
of the said venture without the need to invest funds.

 

13.5 Notwithstanding
the above, sections 13.1 to 13.3 shall not apply to minority stakes and/or passive investment and /or non controlling equity held
by either company in competitive projects.

 

14. Governing
Law and Dispute Resolution

 

This Agreement shall
be governed by and construed in accordance with the laws of Israel without reference to its conflict of laws principles. Any dispute
arising hereunder shall be referred to the competent courts in Tel Aviv.

 

15. Miscellaneous

 

15.1 Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement
and supersedes all prior agreements, understandings, and negotiations, both written and oral, between the parties with respect
to the subject matter hereof or thereof, including the Memorandum of Understanding, dated June 20, 2018.

 

    10

     

    

 

15.2 Amendments.
Any provision of this Agreement may be amended if, and only if, such amendment is in writing and signed by all parties hereto.

 

15.3 No
Waivers. No failure or delay by a Founder in exercising any right or remedy under this Agreement shall operate as a waiver
thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right or remedy.

 

15.4 Assignment.
No Founder may assign this Agreement nor his rights or obligations hereunder without the prior written consent of the other Founder,
except to its Affiliates (for as long as they continue to be its Affiliates and subject to Section 5.1 above).

 

15.5 Successors
and Assigns. The provisions of this Agreement shall be binding upon and inure to the benefit of the Founders and their
respective successors and permitted assigns.

 

15.6 Severability.
In the event that any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be
limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and
enforceable.

 

15.7 Counterparts.
This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures to each were upon the same instrument.

 

15.8 No
Third Party Beneficiaries. The parties agree that there are no third party beneficiaries to this Agreement.

 

15.9Acceptance
by the Company.The Founders will procure endorsement of this Agreement by the Company as soon as it is formed, signifying
the Company’s agreement with, and acceptance of, the Agreement’s terms insofar as they affect the Company.

 

15.10 Termination.
If, for whatever reason, the Founders do not approve the Business Plan by June 30, 2019, this Agreement shall expire at such time,
and the Founders shall cooperate in winding down the Company.

 

[signature page follows]

 

    11

     

    

  

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the day first above written.

 

	Cannabics Pharmaceuticals, Inc.	 	Wize Pharma, Inc.
	 	 	 
	/s/ Eyal Barad	 	/s/ Or Eisenberg
	Name:	 	Name: Or Eisenberg
	Title:	 	Title: CFO & Acting CEO
	Date:	 	Date: February 7, 2019

   

    12EX-10.1

 Exhibit 10.1 

TERMINATION AGREEMENT 

This TERMINATION AGREEMENT (this “Agreement”), dated as of February 11, 2019 (the “Effective Date”), is
by and among Bristow Group Inc., a Delaware corporation (“Parent”), Bear Acquisition I, LLC, a Delaware limited liability company and direct wholly owned subsidiary of Parent (the “Purchaser”), Columbia Helicopters,
Inc., an Oregon corporation (the “Company”), the persons listed on Schedule 1 to the Stock Purchase Agreement (the “Shareholders”) and Nancy C. Lematta, in her capacity as the Shareholder Representative (as
defined in the Stock Purchase Agreement). 
 WHEREAS, Parent, the Purchaser, the Company, the Shareholders and the Shareholder
Representative entered into the Stock Purchase Agreement, dated as of November 9, 2018 (the “Stock Purchase Agreement”; capitalized terms used in this Agreement and not defined in this Agreement have the meanings assigned to
such terms in the Stock Purchase Agreement); 
 WHEREAS, each Shareholder has irrevocably appointed Nancy C. Lematta as such
Shareholder’s true and lawful attorney-in-fact and agent, to act on behalf of such Shareholder with respect to the Stock Purchase Agreement and the subject matter
of the Stock Purchase Agreement; and 
 WHEREAS, the parties desire to terminate the Stock Purchase Agreement by mutual written consent, and
to release each other from all claims, obligations and liabilities arising out of, in connection with or relating to the Stock Purchase Agreement, the Transaction Documents and any ancillary agreements, the Transactions, or the transactions
contemplated by the Transaction Documents and any ancillary agreements, in each case, on the terms and subject to the conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the covenants and agreements set forth in this Agreement and for other good and valuable consideration,
the receipt and sufficiency of which are acknowledged, and intending to be legally bound, the parties agree as follows: 

1.    Termination. Pursuant to Section 12.1(a) thereof, the Stock Purchase Agreement, including all schedules,
appendices and exhibits thereto, and all Transaction Documents, are terminated immediately effective upon the later of the execution and delivery of this Agreement or the receipt by the Company of the payment described in Section 2 below (the
“Termination Time”) and without any further action by any party and, notwithstanding anything to the contrary in this Agreement, the Stock Purchase Agreement or the Transaction Documents, the Stock Purchase Agreement and the
Transaction Documents are terminated in their entirety and shall be of no further force or effect whatsoever (the “Termination”), provided that Section 10.2 of the Stock Purchase Agreement and the Confidentiality Agreement
shall survive the Termination according to their respective terms. 
 2.    Fees. In connection with the
Termination and in consideration of the agreements made by the Company and the Shareholders, including the agreement to terminate Section 12.3 of the Stock Purchase Agreement, Parent will pay to the Company, no later than 3:00 p.m. EST on the
Effective Date, $20,000,000 (the “Payment”) by wire transfer to the account specified in attached Exhibit A. The Payment includes reimbursement of expenses of the Company and the Shareholders incurred in connection with the
negotiation, execution and performance of the Stock Purchase Agreement, and the matters set forth in Section 12.3(c) of the Stock Purchase Agreement. 

 3.    Mutual Release; Disclaimer of Liability. Each of Parent,
Purchaser, and the Company, on behalf of itself and each of its respective successors Affiliates, divisions, assignees, employees, Agents, shareholders and advisors, and the Shareholder Representative and each of the Shareholders, on behalf of
itself and each of their respective successors, Affiliates, heirs, administrators, trustees, devisees, legatees, Agents and advisors (the “Releasors”), does, to the fullest extent permitted by law, fully release, forever discharge
and covenant not to sue any other party, any of their respective successors, Affiliates, divisions or assignees, and any of their respective present or former employees, Agents, shareholders, financial advisors, auditors, heirs, administrators,
devisees or legatees (collectively, the “Releasees”), from and with respect to any and all liability, claims, rights, actions, causes of action, suits, liens, obligations, accounts, debts, demands, agreements, promises, liabilities,
controversies, costs, charges, damages, expenses and fees (including attorney’s, financial advisor’s, lender’s or other fees) (“Claims”), howsoever arising, whether based on any national, federal, state or foreign
law, principle of common law or right of action, known or unknown, mature or unmatured, contingent or fixed, liquidated or unliquidated, accrued or unaccrued, which Releasors, or any of them, ever had or now have or can have or shall or may
hereafter have (or which might be asserted derivatively on their behalf) against the Releasees, or any of them, in connection with, arising out of or related to the Stock Purchase Agreement or any Transaction Document or the Transactions or the
transactions contemplated by the Transaction Documents or any ancillary agreement. The release contemplated by this Section 3 is intended to be as broad as permitted by law and is intended to, and does, extinguish all Claims of any kind
whatsoever, whether in law or equity or otherwise, that are based on or relate to facts or conditions or actions (known or unknown) that have existed or occurred at any time prior to the Termination Time. Each of the Releasors expressly waives to
the fullest extent permitted by law the provisions, rights, and benefits of California Civil Code § 1542 (or any similar law), which provides: 

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of
executing the release, which if known by him or her must have materially affected his or her settlement with the debtor. 
 Nothing in this
Section 3 shall apply to (a) any action by any party to enforce the rights and obligations imposed pursuant to this Agreement, including (without limitation) the obligations of Parent under Section 2 of this Agreement or (b) any
breach of the Confidentiality Agreement. 
 4.    Publicity. The parties mutually agree to issue a joint press
release in the form attached as Exhibit B to this Agreement regarding this Agreement and the Termination. 

5.    Confidentiality. The parties agree that the Confidentiality Agreement will survive the Termination, and will
remain in full force and effect in accordance with its terms. 
 6.    Expenses. Except for the provisions of
Section 16, all costs and expenses (including all fees and expenses of counsel, accountants, investment bankers, experts and consultants to a party to this Agreement and its affiliates) incurred by a party or on its behalf in connection with or
related to the authorization, preparation, negotiation, execution and performance of the Stock Purchase Agreement, the Transaction Documents or this Agreement and the Transactions or the transactions contemplated by the Transaction Documents or any
ancillary agreement (“Expenses”) shall be paid by the party incurring such Expenses. Each party to this Agreement shall indemnify the others against any claims related to the foregoing. 

  
 -2- 

 7.    Representations and Warranties. Each party represents and
warrants to the other that: (a) such party has all requisite power and authority to enter into this Agreement and to take the actions contemplated by this Agreement; (b) the execution and delivery of this Agreement and the actions
contemplated by this Agreement have been duly authorized by all necessary corporate or other action on the part of such party, including any necessary approval of each of such party’s relevant boards; and (c) this Agreement has been duly
and validly executed and delivered by such party and constitutes a legal, valid and binding obligation of such party enforceable against such party in accordance with its terms. 

8.    Further Assurances. Each party shall, and shall cause its Affiliates to, cooperate with each other in the
taking of all actions necessary, proper or advisable under this Agreement and applicable laws to effectuate the Termination. Without limitation and to the extent necessary, the Company and Parent will cooperate with each other to provide any
required notice to any Government Authorities and third parties of the termination of the Stock Purchase Agreement and the Transactions. 

9.    Third-Party Beneficiaries. Except for the provisions of Section 3 of this Agreement, with respect to
which each Releasee is an expressly intended third party beneficiary, this Agreement is not intended to (and does not) confer on any person other than the parties any rights or remedies or impose on any person other than the parties any obligations.

 10.    Entire Agreement. This Agreement and the Confidentiality Agreement constitute the entire agreement
between the parties with respect to the subject matter of this Agreement and supersede all other agreements and understandings, both written and oral, between the parties with respect to the subject matter of this Agreement. 

11.    Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of
New York, without giving effect to any choice of law or conflicting provision or rule (whether of the State of New York or any other jurisdiction) that would cause the laws of any jurisdiction other than the State of New York to be applied. In
furtherance of the foregoing, the internal laws of the State of New York will control the interpretation and construction of this Agreement, even if under New York’s choice of law or conflict of law analysis, the substantive laws of another
jurisdiction would ordinarily apply. 
 12.    Forum Selection; Waiver of Jury Trial. ANY SUIT, ACTION, OR
PROCEEDING ARISING OUT OF, RELATING TO OR BASED ON THIS AGREEMENT WILL BE HEARD, TRIED, AND/OR ARBITRATED IN NEW YORK, AND EACH PARTY SUBMITS AND CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED IN NEW YORK, NEW YORK.
EACH PARTY AGREES THAT IT IS SUBJECT TO PERSONAL JURISDICTION IN NEW YORK. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO A PARTY’S ADDRESS AS SET FORTH IN THE STOCK PURCHASE AGREEMENT WILL BE EFFECTIVE SERVICE OF PROCESS FOR
ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD
OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN 

  
 -3- 

 
BROUGHT IN AN INCONVENIENT FORUM. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT ANY CONTROVERSY THAT MAY ARISE OUT OF, RELATE TO OR BE
BASED UPON THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES. ACCORDINGLY, EACH PARTY TO THIS AGREEMENT IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, TRIAL BY JURY IN ANY SUIT,
ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED UPON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, RELATING TO OR BASED UPON THIS AGREEMENT. EACH PARTY ACKNOWLEDGES THAT (a) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (b) IT HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (c) IT MAKES THIS WAIVER VOLUNTARILY, AND (d) IT HAS BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 12. 

13.    Counterparts. This Agreement may be executed in any number of separate counterparts, each such counterpart
being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. 

14.    Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction or other governmental authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any party to this Agreement. Upon such a determination, the parties to this
Agreement shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner. 

15.    Confidential Information. 

(a)    Promptly after the Effective Date, Parent will, or will direct its third-party Agents to: 

(i)    Remove from Parent’s website the presentation entitled “Columbia Helicopters Business
Review” ; and 
 (ii)    Direct its third-party Agents to terminate all third party access to any
data rooms that (x) are hosted or controlled by Parent or any of its Affiliates or Agents, and (y) contain any confidential information of Columbia. 

The parties specifically agree that monetary damages would be inadequate to compensate the Company for breaches or threatened breaches of this
Section 15(a). Accordingly, and because of the potential for irreparable harm in the event of such breaches, the Company may, in addition to its other remedies, seek equitable or injunctive relief to address an actual or threatened breach of
this Section 15(a), without having to prove specific damages or post a bond or other security. 

  
 -4- 

 (b)    Promptly after the Effective Date, each of Parent and the Company
will comply with its obligations relating to the return or destruction of confidential information of the other party pursuant to the Confidentiality Agreement. This Agreement shall constitute the Company’s request that Parent destroy or return
to the Company all confidential information of the Company, and Parent’s request that the Company destroy or return to Parent all confidential information of Parent, in each case pursuant to the terms of the Confidentiality Agreement. 

16.    Attorney Fees. If a suit in any state or federal court, action, arbitration, or other proceeding of any
nature between or among the parties to this Agreement is instituted in connection with any controversy, interpretation, or enforcement of any rights under or related to this Agreement, the party substantially prevailing will be entitled to recover
its attorney, paralegal, accountant, and expert fees, and all other reasonably necessary fees, costs, and expenses actually incurred in connection with that proceeding as determined by the court or arbitrator at trial or arbitration, or in any
appeal or other post-judgment proceeding, in addition to all other amounts provided by law. The court or arbitrator(s) hearing the matter will determine which party is substantially prevailing taking into account the number and importance of all
claims and defenses, the outcomes of those claims, and any offers of settlement made by the parties. 
 [signature page follows] 

  
 -5- 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by and on behalf of
each the undersigned as of the Effective Date. 
  

			
	BEAR ACQUISITION I, LLC
		
	By:	 	 /s/ Brian J. Allman

	Name:	 	Brian J. Allman
	Title:	 	President
	
	BRISTOW GROUP INC. 
		
	By:	 	 /s/ L. Don Miller

	Name:	 	L. Don Miller
	Title:	 	Senior Vice President and Chief Financial Officer
	
	COLUMBIA HELICOPTERS, INC. 
		
	By:	 	 /s/ Steven E. Bandy

	Name:	 	Steven E. Bandy
	Title:	 	President and Chief Executive Officer
	
	SHAREHOLDER REPRESENTATIVE
	
	 /s/ Nancy C. Lematta

	Nancy C. Lematta, Shareholder Representative
	
	SHAREHOLDERS
	
	 /s/ Marci Ann Walsh

	Marci Ann Walsh
	
	 /s/ Wesley Bart Lematta

Wesley Bart Lematta

 [Signature Page to Termination Agreement] 

 
			
	 /s/ Jon A. Lazzaretti

	Jon A. Lazzaretti
	
	LEMATTA FAMILY TRUST DATED NOVEMBER 18, 2010, AS AMENDED
		
	By:	 	 /s/ Nancy C. Lematta

	Name:	 	Nancy C. Lematta, Trustee
	
	WESLEY G. LEMATTA RESIDUARY TRUST I DATED DECEMBER 24, 2009
		
	By:	 	 /s/ Nancy C. Lematta

	Name:	 	Nancy C. Lematta, Trustee
	
	WESLEY G. LEMATTA RESIDUARY TRUST II DATED DECEMBER 24, 2009
		
	By:	 	 /s/ Nancy C. Lematta

	Name:	 	Nancy C. Lematta, Trustee
	
	NANCY ELIZABETH LEMATTA TRUST DATED DECEMBER 31, 1976
		
	By:	 	 /s/ Nancy C. Lematta

	Name:	 	Nancy C. Lematta, Trustee

 [Signature Page to Termination Agreement] 

 
			
	LEMATTA 2012 IRREVOCABLE TRUST DATED DECEMBER 17, 2012 FBO NANCY ELIZABETH LEMATTA
		
	By:	 	 /s/ Gregory A. Damico

	Name:	 	Gregory A. Damico, Trustee
		
	By:	 	 /s/ Stanley Y. Wilson

	Name:	 	Stanley Y. Wilson, Trustee

 [Signature Page to Termination Agreement] 

 
			
	LEMATTA 2012 IRREVOCABLE TRUST DATED DECEMBER 17, 2012 FBO MARCI ANN WALSH
		
	By:	 	 /s/ Gregory A. Damico

	Name:	 	Gregory A. Damico, Trustee
		
	By:	 	 /s/ Stanley Y. Wilson

	Name:	 	Stanley Y. Wilson, Trustee
	
	LEMATTA 2012 IRREVOCABLE TRUST DATED DECEMBER 17, 2012 FBO WESLEY BART LEMATTA
		
	By:	 	 /s/ Gregory A. Damico

	Name:	 	Gregory A. Damico, Trustee
		
	By:	 	 /s/ Stanley Y. Wilson

	Name:	 	Stanley Y. Wilson, Trustee
	
	SEPARATE SHARE OF MICHAEL A. FAHEY OF THE FAHEY FAMILY 2016 TRUST U/A/D MARCH 3, 2016
		
	By:	 	 /s/ Michael A. Fahey

	Name:	 	Michael A. Fahey, Co-Trustee
		
	By:	 	 /s/ Penny L. Fahey

	Name:	 	Penny L. Fahey, Co-Trustee

 [Signature Page to Termination Agreement] 

 EXHIBIT A 

Wire Transfer Information 
 [Redacted]

  
 Exhibit A 

 EXHIBIT B 

Press Release 
 (see
attached) 

  
 Exhibit B 

			
	

	  	

 Bristow and Columbia Helicopters Terminate Proposed Transaction 

HOUSTON, TX – February 11, 2018 Bristow Group Inc. (NYSE: BRS) and Columbia Helicopters, Inc. today announced
that Bristow and Columbia have mutually agreed to terminate Bristow’s agreement to acquire Columbia. In connection with the termination, Bristow has paid $20 million to Columbia. Bristow, Columbia and Columbia’s shareholders have
agreed to release each other from all claims in connection with the purchase agreement and the related transactions. 
 Thomas C. Knudson, the Chairman of
the Board of Directors of Bristow, stated “The decision to enter into a mutual termination of the purchase agreement was based on a number of developments following the entry into the agreement, which led both Bristow and Columbia to conclude
that it was not possible to combine the two companies at this time. We continue to value our relationship with Columbia and look forward to having the opportunity to work together in the future.” Steve Bandy, the President and Chief Executive
Officer of Columbia, stated “We continue to believe in the potential for collaboration between Bristow and Columbia, and the companies are actively considering mutually beneficial opportunities to work together.” 

ABOUT BRISTOW GROUP INC. 
 Bristow Group Inc. is
the leading global industrial aviation services provider offering helicopter transportation, search and rescue (SAR) and aircraft support services to government and civil organizations worldwide. Bristow has major transportation operations in the
North Sea, Nigeria and the U.S. Gulf of Mexico, and in most of the other major offshore oil and gas producing regions of the world, including Australia, Brazil, Canada, Russia and Trinidad. Bristow provides SAR services to the private sector
worldwide and to the public sector for all of the U.K. on behalf of the Maritime and Coastguard Agency. For more information, visit bristowgroup.com. 

 ABOUT COLUMBIA HELICOPTERS, INC 

Columbia Helicopters is the global leader in heavy-lift helicopter operations and trusted expert in maintenance, repair and overhaul services. The company
owns, operates and maintains a fleet of Columbia Model 107-II Vertol, Columbia Model 234 Chinook, and Columbia Model CH-47D Chinook helicopters. These aircraft are
operated around the world, providing passenger and cargo services to customers and in various end-markets. In addition, Columbia Helicopters supports commercial and government operators with a comprehensive
range of responsive life-cycle support and MRO services, from tip to tail, in the hangar or in the field maintenance. Columbia Helicopters holds Type and Production Certificates for the Columbia Model 234 Chinook and Columbia Model 107-II Vertol, and a restricted category Type Certificate for the Columbia Model CH-47D Chinook. Columbia Helicopters is a factory-authorized service center for the Honeywell T55-714 and a NAVAIR-approved MRO facility. To learn more, visit http://www.colheli.com/. 
 FORWARD-LOOKING STATEMENTS
DISCLOSURE 
 Statements contained in this news release that state Bristow’s or management’s intentions, hopes, beliefs, expectations or
predictions of the future are forward-looking statements. These forward-looking statements include statements regarding potential for collaboration with Columbia, future opportunities, market and industry conditions, and other statements identified
by words such as “will,” “expect,” “believe,” “anticipate,” “estimate,” “should,” “intend,” “plan,” “potential,” “predict,” “project,”
“aim,” “hope,” “predict,” and similar words, phrases and expressions, although not all forward-looking statements include such words, phrases or expressions. It is important to note that the Company’s actual
results could differ materially from those projected in such forward-looking statements. Factors that could cause events or results to differ materially from those anticipated include but are not limited to the following: fluctuations in the demand
for our services; fluctuations in worldwide prices of and supply and demand for oil and natural gas; fluctuations in levels of oil and natural gas production, exploration and development activities; the impact of competition; actions by customers
and suppliers; the risk of reductions in spending on industrial aviation services by governmental agencies; changes in tax and other laws and regulations; changes in foreign exchange rates and controls; risks associated with international
operations; operating risks inherent in our business, including the possibility of declining safety performance; general economic conditions including the capital and credit markets; our inability to obtain financing on favorable terms, whether
caused by our financial position, lower debt credit ratings, unstable markets or otherwise; our ability to pay, refinance or restructure our debt 

 
and aircraft lease commitments; the risk of grounding of segments of our fleet for extended periods of time or indefinitely; our ability to re-deploy our
aircraft to regions with greater demand; our ability to acquire additional aircraft and dispose of older aircraft through sales into the aftermarket; the possibility that we do not achieve the anticipated benefit of our fleet investment program;
availability of employees; and political instability, war or acts of terrorism in any of the countries where we operate. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking
statements is contained from time to time in the Company’s SEC filings, including but not limited to the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2018 and
quarterly report on Form 10-Q for the quarter ended September 30, 2018. Bristow Group Inc. disclaims any intention or obligation to revise any forward-looking statements, including financial estimates,
whether as a result of new information, future events or otherwise. 
 Investor Relations 

Linda McNeill 
 Director, Investor Relations 

+1 713.267.7622 
 Global Media Relations 

Adam Morgan 
 Director, Global Communications 

+1 281.253.9005

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]